Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108


Novel targeted therapies for mantle cell lymphoma.

Alinari L, Christian B, Baiocchi RA.

Oncotarget. 2012 Feb;3(2):203-11.


Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma.

Alinari L, Yu B, Christian BA, Yan F, Shin J, Lapalombella R, Hertlein E, Lustberg ME, Quinion C, Zhang X, Lozanski G, Muthusamy N, Prætorius-Ibba M, O'Connor OA, Goldenberg DM, Byrd JC, Blum KA, Baiocchi RA.

Blood. 2011 Apr 28;117(17):4530-41. doi: 10.1182/blood-2010-08-303354.


FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death.

Alinari L, Mahoney E, Patton J, Zhang X, Huynh L, Earl CT, Mani R, Mao Y, Yu B, Quinion C, Towns WH, Chen CS, Goldenberg DM, Blum KA, Byrd JC, Muthusamy N, Praetorius-Ibba M, Baiocchi RA.

Blood. 2011 Dec 22;118(26):6893-903. doi: 10.1182/blood-2011-06-363879.


Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas.

Gupta P, Goldenberg DM, Rossi EA, Cardillo TM, Byrd JC, Muthusamy N, Furman RR, Chang CH.

Blood. 2012 Apr 19;119(16):3767-78. doi: 10.1182/blood-2011-09-381988.


[Effects of the phosphoinostitide-3'-kinase delta inhibitor, CAL-101, in combination with Bortezomib on mantle lymophma cells and exploration of its related mechanism].

Qu F, Xia B, Li X, Guo S, Zhang L, Tian C, Yu Y, Zhang Y.

Zhonghua Zhong Liu Za Zhi. 2015 Jun;37(6):412-7. Chinese.


Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma.

Rosich L, Xargay-Torrent S, López-Guerra M, Campo E, Colomer D, Roué G.

Clin Cancer Res. 2012 Oct 1;18(19):5278-89. doi: 10.1158/1078-0432.CCR-12-0351.


Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736.

Restelli V, Chilà R, Lupi M, Rinaldi A, Kwee I, Bertoni F, Damia G, Carrassa L.

Oncotarget. 2015 Nov 10;6(35):37229-40. doi: 10.18632/oncotarget.5954.


Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.

Chiron D, Di Liberto M, Martin P, Huang X, Sharman J, Blecua P, Mathew S, Vijay P, Eng K, Ali S, Johnson A, Chang B, Ely S, Elemento O, Mason CE, Leonard JP, Chen-Kiang S.

Cancer Discov. 2014 Sep;4(9):1022-35. doi: 10.1158/2159-8290.CD-14-0098.


Novel treatment for mantle cell lymphoma including therapy-resistant tumor by NF-κB and mTOR dual-targeting approach.

Chaturvedi NK, Rajule RN, Shukla A, Radhakrishnan P, Todd GL, Natarajan A, Vose JM, Joshi SS.

Mol Cancer Ther. 2013 Oct;12(10):2006-17. doi: 10.1158/1535-7163.MCT-13-0239.


Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management.

Vose JM.

Am J Hematol. 2013 Dec;88(12):1082-8. doi: 10.1002/ajh.23615. Review.


Temsirolimus for the treatment of mantle cell lymphoma.

Hess G.

Expert Rev Hematol. 2009 Dec;2(6):631-40. doi: 10.1586/ehm.09.57. Review.


Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era.

Pérez-Galán P, Dreyling M, Wiestner A.

Blood. 2011 Jan 6;117(1):26-38. doi: 10.1182/blood-2010-04-189977. Review.


The synergistic effect of BCR signaling inhibitors combined with an HDAC inhibitor on cell death in a mantle cell lymphoma cell line.

Hagiwara K, Kunishima S, Iida H, Miyata Y, Naoe T, Nagai H.

Apoptosis. 2015 Jul;20(7):975-85. doi: 10.1007/s10495-015-1125-1.


Flipping the cyclin D1 switch in mantle cell lymphoma.

Hasanali Z, Sharma K, Epner E.

Best Pract Res Clin Haematol. 2012 Jun;25(2):143-52. doi: 10.1016/j.beha.2012.03.001. Review.


Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics.

Jares P, Colomer D, Campo E.

Nat Rev Cancer. 2007 Oct;7(10):750-62. Review.


Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma.

Peponi E, Drakos E, Reyes G, Leventaki V, Rassidakis GZ, Medeiros LJ.

Am J Pathol. 2006 Dec;169(6):2171-80.


FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma.

Liu Q, Alinari L, Chen CS, Yan F, Dalton JT, Lapalombella R, Zhang X, Mani R, Lin T, Byrd JC, Baiocchi RA, Muthusamy N.

Clin Cancer Res. 2010 Jun 15;16(12):3182-92. doi: 10.1158/1078-0432.CCR-09-2484.


Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways.

Fernàndez V, Hartmann E, Ott G, Campo E, Rosenwald A.

J Clin Oncol. 2005 Sep 10;23(26):6364-9. Review.


Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma.

Rahal R, Frick M, Romero R, Korn JM, Kridel R, Chan FC, Meissner B, Bhang HE, Ruddy D, Kauffmann A, Farsidjani A, Derti A, Rakiec D, Naylor T, Pfister E, Kovats S, Kim S, Dietze K, Dörken B, Steidl C, Tzankov A, Hummel M, Monahan J, Morrissey MP, Fritsch C, Sellers WR, Cooke VG, Gascoyne RD, Lenz G, Stegmeier F.

Nat Med. 2014 Jan;20(1):87-92. doi: 10.1038/nm.3435.

Items per page

Supplemental Content

Support Center